Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Better Buy: UiPath vs. DocuSign

TheMotleyFool

0 0

UiPath (NYSE: PATH) and DocuSign (NASDAQ: DOCU) burned a lot of investors over the past few months. UiPath went public at $56 last April and surged to an all-time of $85.12 the following month, but it now trades at about $22. DocuSign, which went public back in 2018, closed at an all-time high of $310.05 last September, but now trades below $110 per share.

Investors abandoned both high-growth software stocks amid concerns about their slowing growth, peaking margins, and red ink. The broader rotation away from higher-growth tech stocks exacerbated that sell-off.

But did investors prematurely give up on these two disruptive companies? Let's take a fresh look at both businesses to find out.

Source Fool.com

Like: 0

PATH

Share